A Phase 2 interventional study of Anakinra and Placebo in Juvenile Chronic Arthritis, sponsored by Amgen. Completed. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2009-11-26.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
This study's enrollment of 86 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Browse Arthritis, Juvenile studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Drug: Placebo
Drug: Anakinra
anakinra
placebo
The primary outcome of the study was to evaluate the safety of anakinra
Time frame: 28 weeks
No study locations are listed for this record.
The record gives a start of Jul 2000, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein